The Oral PCSK9 inhibitor enlicitide for hypercholesterolemia

  • Eur J Intern Med. 2026 Mar 14:106835. doi: 10.1016/j.ejim.2026.106835.
Mohammed A Elbahloul  1 ,  Aliaa Gamal  2 ,  Islam Y Elgendy  3
Affiliations
  • 1. Faculty of Medicine, Kafr El-Shaikh University, Kafr El Shaikh, Egypt. Electronic address: [email protected].
  • 2. Clinical Pharmacy Department, Faculty of Pharmacy, Deraya University, Minia, Egypt.
  • 3. Division of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky, Lexington, USA.
PMID: 41833476 DOI: 10.1016/j.ejim.2026.106835
Keywords
Enlicitide; Hypercholesterolemia; Oral PCSK9 Inhibitor; meta-analysis.
Products